OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Markman on the Concept of Biosimilars in Oncology

November 27th 2018

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, and 2018 Giant of Cancer Care® for Gynecological Cancers, discusses the concept of biosimilars in oncology.

Dr. Clark on the Role of Cytoreductive Nephrectomy in RCC

November 27th 2018

Peter Clark, MD, medical oncologist, Levine Cancer Institute, Atrium Health, discusses the role of cytoreductive nephrectomy in the treatment of patients with renal cell carcinoma (RCC).

Dr. Drilon Discusses the FDA Approval of Larotrectinib

November 27th 2018

Alexander Drilon, MD, medical oncologist, clinical director, Early Drug Development Service, Memorial Sloan Kettering Cancer Center, discusses the FDA approval larotrectinib in NTRK-positive cancers.

Dr. Verstovsek on JAK Inhibition in Polycythemia Vera

November 26th 2018

Srdan Verstovsek, MD, PhD, director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses JAK inhibition in the treatment of polycythemia vera.

Dr. Tawbi on Checkpoint Inhibition in Melanoma

November 26th 2018

Hussein A. Tawbi, MD, PhD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the promise of checkpoint inhibition in the treatment of melanoma.

Dr. Link on Evolution of Treatment in Pediatric Cancer

November 22nd 2018

Michael Link, MD, professor of pediatrics, Stanford Cancer Institute, 2018 Giant of Cancer Care in Pediatrics, discusses the evolution of treatment in pediatric cancer.

Dr. Choueiri on Checkpoint Inhibitor/TKI Combinations in RCC

November 22nd 2018

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses combinations of checkpoint inhibitors and TKIs for the treatment of renal cell carcinoma.

Dr. O'Regan on Impact of Targeted Agents in HER2+ Breast Cancer

November 22nd 2018

Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses the impact of targeted agents in HER2-positive breast cancer.

Dr. Cercek on Chemotherapy Resistance in dMMR Rectal Cancer

November 20th 2018

Andrea Cercek, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses chemotherapy resistance in mismatch repair deficient rectal cancer.

Dr. Rosenberg Discusses Challenges in Metastatic Urothelial Carcinoma

November 20th 2018

Jonathan E. Rosenberg, MD, medical oncologist, chief, Genitourinary Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses challenges in the treatment of patients with metastatic urothelial carcinoma.

Dr. Ganjoo on the Treatment of Early-Stage Uterine Leiomyosarcoma

November 20th 2018

Kristen N. Ganjoo, MD, associate professor of medicine, Stanford University Medical Center, Stanford Medicine, discusses the treatment of patients with early-stage uterine leiomyosarcoma.

Dr. Parekh on Evolving Treatment Landscape in Myeloma

November 20th 2018

Samir Parekh, MBBS, associate professor of medicine, Hematology/Oncology, Mount Sinai Hospital, discusses the evolving treatment landscape in myeloma.

Dr. Westin on Emerging PARP Inhibitors in Ovarian Cancer

November 20th 2018

Shannon N. Westin, MD, MPH, clinical investigator, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses PARP inhibitors being tested in clinical trials.

Dr. Borgen on Precision Medicine in Breast Cancer

November 20th 2018

Patrick Borgen, MD, chair, Department of Surgery, director, Breast Cancer, Maimonides Medical Center, discusses the implementation of precision medicine in breast cancer.

Dr. Morris Discusses PSMA-Targeted Imaging in mCRPC

November 20th 2018

Michael J. Morris, MD, medical oncologist, clinical director, Genitourinary Medical Oncology Service, Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses the use of prostate-specific membrane antigen (PSMA)-targeted imaging in patients with metastatic castration-resistant prostate cancer.

Dr. Rugo on the Optimal Setting for Biosimilar Evaluation

November 20th 2018

Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the optimal setting for biosimilar evaluation.

Dr. Cohen Discusses CAR T-Cell Therapy in MCL

November 20th 2018

Jonathon B. Cohen, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, discusses the use of CAR T-cell therapy in patients with mantle cell lymphoma.

Dr. Figlin on Treatment Strategies in Advanced RCC

November 20th 2018

Robert A. Figlin, MD, director, Division of Hematology/Oncology, Steven Spielberg Professor of Biomedical Sciences and Medicine, Cedars-Sinai Medical Center, discusses treatment strategies for patients with advanced renal cell carcinoma.

Dr. Perez-Soler on Current Status of Biomarkers in SCLC

November 20th 2018

Roman Perez-Soler, MD, chairman of the Department of Oncology and chief of the Division of Medical Oncology at Montefiore Medical Center, discusses the current status of biomarkers of small cell lung cancer.

Dr. Perl on Evolving Treatment in AML

November 19th 2018

Alexander E. Perl, MD, assistant professor of medicine, University of Pennsylvania, discusses the evolving treatment landscape in acute myeloid leukemia.